Core Insights - Eli Lilly is projected to become the highest-selling biopharmaceutical company globally by 2030, with sales expected to reach $113 billion, significantly surpassing Novo Nordisk's anticipated $84 billion [2] - The diabetes and obesity drug market is expected to dominate, with an average annual growth rate of 20% from 2024 to 2030 [2] - GLP-1 receptor agonists and related drugs are expected to account for nearly 9% of the global prescription drug market by 2030, marking a significant category in the pharmaceutical landscape [2] Group 1: Sales Projections - Eli Lilly's diabetes treatment Mounjaro is expected to become the best-selling drug globally by 2030, with projected sales of $36 billion [4] - Novo Nordisk's drugs, including Ozempic and Wegovy, are also expected to rank among the top ten best-selling drugs, with sales of $24.4 billion and $18.1 billion respectively [4] - Three clinical-stage obesity drugs are anticipated to enter the global sales top ten by 2030, with Eli Lilly's Orforglipron and Retatrutide projected to achieve sales of $12.7 billion and $5.6 billion respectively [4] Group 2: Company Rankings and Growth - The top seven companies in global prescription drug sales for 2024 are projected to be Johnson & Johnson, AbbVie, Merck, Roche, Pfizer, AstraZeneca, and Novartis, with sales ranging from $50.2 billion to $55.7 billion [5] - Eli Lilly and Novo Nordisk are expected to surpass these companies by 2030, with AbbVie showing significant growth to $75.3 billion, driven by its immunology drugs [5][6] - Sanofi is projected to grow from $44.2 billion in 2024 to $64.8 billion by 2030, largely due to its drug Dupixent [6] Group 3: Market Dynamics - Roche is expected to see its overall prescription drug sales increase from $52.5 billion to $66.3 billion by 2030, despite not having any single drug in the top ten [7] - Merck's sales are projected to grow from $54.3 billion to $60 billion, with Keytruda facing competition from biosimilars [7] - The rapid expansion of the diabetes and obesity treatment market is reshaping the pharmaceutical industry, positioning Eli Lilly and Novo Nordisk as new leaders [8]

Core Viewpoint - The article discusses the rising trend of weight loss among celebrities and entrepreneurs, highlighting the effectiveness of GLP-1 medications like Semaglutide and Tirzepatide in achieving significant weight loss results [2][15][31]. Group 1: Celebrity Weight Loss Stories - Yan Rujing lost 55 pounds (approximately 24.9 kg) over six months, starting from a weight of 196 pounds (approximately 89 kg) with a body fat percentage of 48.6% and a BMI of 40.27, indicating severe obesity [4][6]. - Lamei Yang achieved a weight loss of 20 pounds (approximately 9.1 kg) in just one month during the filming of "Sisters Who Make Waves," through an intense training regimen of 8 hours daily [7][11]. - Ma Weiwei lost 20 pounds (approximately 9.1 kg) in 45 days, adopting a low-carb diet and rigorous exercise, while also managing her mental health challenges related to depression [12][14]. Group 2: GLP-1 Medications Effectiveness - Semaglutide has shown an average weight loss of 15% in obese patients, significantly outperforming previous weight loss medications that typically resulted in a 5%-10% reduction [26][30]. - In clinical trials, Semaglutide demonstrated that over one-third of participants lost more than 20% of their body weight, while the placebo group only lost 2.4% [28]. - Tirzepatide has also proven effective, with studies showing an average weight loss of 15.4% to 22.9% in patients, significantly reducing the risk of diabetes progression [31][34].

Core Viewpoint - The article discusses the weight loss journey of Yang Tianzhen, highlighting her recent physical transformation and the methods she employed, including exercise and dietary changes, while clarifying that her weight loss is not solely due to traditional dieting methods [4][8]. Group 1: Yang Tianzhen's Weight Loss Journey - Yang Tianzhen has recently shared her weight loss progress, showcasing her commitment to exercise, particularly badminton, which has resulted in visible muscle definition [2][7]. - Despite public admiration for her efforts, there are mixed reactions, with some questioning the authenticity of her weight loss and others noting her previous statements against dieting [4]. - Yang underwent gastric surgery five years ago to manage diabetes, emphasizing that her primary motivation for the surgery was health-related rather than weight loss [4][5]. Group 2: Celebrity Weight Loss Trends - The article notes a surge in weight loss stories among celebrities, with many utilizing medications like Semaglutide and Tirzepatide for weight management [9]. - Elon Musk reported a weight loss of 30 pounds (approximately 27.2 kg) using Semaglutide [9]. - Other celebrities, including Whoopi Goldberg and Kelly Clarkson, have also shared their experiences with weight loss medications, highlighting significant weight reductions [11][13]. Group 3: Efficacy of Semaglutide - Clinical trials (STEP series) indicate that Semaglutide can lead to an average weight loss of 15% to 18% in obese patients, significantly outperforming placebo groups [21][26]. - In the STEP 1 trial, participants lost an average of 14.9% of their body weight, with over one-third losing more than 20% [23]. - The FDA approved Semaglutide for long-term weight management in adults with obesity or overweight conditions in June 2021, marking it as a significant advancement in obesity treatment [26]. Group 4: Efficacy of Tirzepatide - The SURMOUNT studies demonstrate that Tirzepatide can achieve substantial weight loss, with participants losing up to 26.6% of their body weight over 72 weeks [31]. - In the SURMOUNT-2 trial, patients with type 2 diabetes lost an average of 15.7% of their body weight, showcasing the drug's effectiveness [29]. - The FDA approved Tirzepatide for obesity treatment based on its promising results in clinical trials [30].